PEDIATRICS / CLINICAL RESEARCH
Comparison of the effectiveness of penicillin and broad-spectrum β-lactam antibiotics in the treatment of community-acquired pneumonia in children
More details
Hide details
1
Department of Pediatrics, University Medical Centre, Maribor, Slovenia
2
Department of Pediatrics, Faculty of Medicine, University of Maribor, Maribor, Slovenia
3
Section of Dental Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Submission date: 2020-04-05
Final revision date: 2020-07-05
Acceptance date: 2020-07-16
Online publication date: 2020-08-20
Publication date: 2026-02-28
Corresponding author
Vojko Berce
Department of Pediatrics
University Medical Centre
Maribor, Slovenia
Phone: +38 631870834
Arch Med Sci 2026;22(1):222-229
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Bacterial community-acquired pneumonia (CAP) in children is caused mostly by Streptococcus pneumoniae. The resistance of pneumococci to penicillin is increasing. However, most guidelines still prefer treatment with narrow-spectrum antibiotics. Therefore, we compared the effect of intravenous treatment with penicillin and broad-spectrum β-lactam antibiotics in children with CAP. The objective of our study was to assess the eligibility of treatment of bacterial CAP with intravenous penicillin.
Material and methods:
We performed a prospective study and included 136 children hospitalised because of bacterial CAP. Patients were treated intravenously with either penicillin G or broad-spectrum β-lactam antibiotic monotherapy. Lung ultrasound and blood tests were performed at admission and after 2 days of treatment. The time interval from the application of antibiotics to permanent defervescence was recorded.
Results:
Eighty-seven (64.0%) patients were treated with penicillin G, and 49 (36.0%) were treated with broad-spectrum β-lactam antibiotics. The median time to persistent defervescence was 5 h in the penicillin group and 8 h in the broad-spectrum group (p = 0.18). There were no significant differences between the treatment regimens regarding the effect on the consolidation sizes or C-reactive protein levels. However, the decrease in the white blood cell count was marginally greater in the penicillin treatment group (p = 0.05).
Conclusions:
We have shown that penicillin is as effective as broad-spectrum antibiotics in the treatment of bacterial CAP in children. Although the resistance of pneumococci to antibiotics is increasing, clinicians should still use penicillin and other narrow-spectrum β-lactam antibiotics in the treatment of bacterial CAP in children.
REFERENCES (34)
1.
urihttp://www.who.int/en/news-room/fact-sheets/detail/pneumonia (last assessed 28th June 2020).
2.
Wysocki J, Sluzewski W, Gutterman E, Jouve S, Moscariello M, Balter I. Active hospital-based surveillance of invasive pneumococcal disease and clinical pneumonia in infants and young children in two Polish counties. Arch Med Sci 2016; 12: 629-38.
3.
Tramper-Stranders GA. Childhood community-acquired pneumonia: a review of etiology and antimicrobial treatment studies. Paediatr Respir Rev 2018; 26: 41-8.
4.
Gupta S, Lodha R, Kabra S. Antimicrobial therapy in community-acquired pneumonia in children. Curr Infect Dis Rep 2018; 20: 47.
5.
Esposito S, Principi N. Defining the aetiology of paediatric community-acquired pneumonia: an unsolved problem. Expert Rev Respir Med 2019; 13: 153-61.
6.
Melander RJ, Zurawski D V, Melander C. Narrow-spectrum antibacterial agents. Medchemcomm 2018; 9: 12-21.
7.
Esposito S, Cohen R, Domingo JD, et al. Antibiotic therapy for pediatric community acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J 2012; 31: 78-85.
8.
Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53: 25-76.
9.
Messinger AI, Kupfer O, Hurst A, Parker S. Management of pediatric community-acquired bacterial pneumonia. Pediatr Rev 2017; 38: 394-409.
10.
Florin TA, Byczkowski T, Gerber JS, Ruddy R, Kuppermann N. Diagnostic testing and antibiotic use in young children with community-acquired pneumonia in the United States, 2008-2015. J Pediatric Infect Dis Soc 2020; 9: 248-52.
11.
Poole NM, Shapiro DJ, Kronman MP, Hersh AL. Ambulatory antibiotic rescribing for children with pneumonia after publication of national guidelines: a cross-sectional retrospective study. Infect Dis Ther 2020; 9: 69-76.
12.
Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN. Antimicrobial susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific region: Results from 20 years of the SENTRY antimicrobial surveillance program (1997-2016). Open Forum Infect Dis 2019; 6 (Suppl 1): 14-23.
13.
Čižman M. Beović B. How to Prescribe Antimicrobial Drugs in Hospital. 2nd ed. Slovenian Medical Association, Ljubljana 2013.
14.
urihttp://www.imi.si/strokovnazdruženja/skuopz/dokumenti/skoupztenenbaum porocilo_2017 CIP.pdf (last assessed 17th January 2020).
15.
Amarilyo G, Glatstein M, Alper A, et al. IV penicillin G is as effective as IV cefuroxime in treating community-acquired pneumonia in children. Am J Ther 2014; 21: 81-4.
16.
Williams DJ, Hall M, Shah SS, et al. Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia. Pediatrics 2013; 132: e1141.
17.
Queen MA, Myers AL, Hall M, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics 2014; 133: 23-9.
18.
Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 (Suppl 2): 1-23.
19.
Stockmann C, Ampofo K, Killpack J, et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc 2018; 7: 46-53.
20.
Korppi M, Kiekara O, Heiskanen-Kosma T, Soimakallio S. Comparison of radiological findings and microbial aetiology of childhood pneumonia. Acta Pædiatr 1993; 82: 360-3.
21.
Shuttleworth DB, Charney E. Leukocyte count in childhood pneumonia. Am J Dis Child 1971; 122: 393-6.
22.
Bhuiyan MU, Blyth CC, West R, et al. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. BMC Pulm Med 2019; 19: 71.
23.
Orso D, Ban A, Guglielmo N. Lung ultrasound in diagnosing pneumonia in childhood: a systematic review and meta-analysis. J Ultrasound 2018; 21: 183-95.
24.
Pereda, MA, Chavez MA, Hooper-Miele CC, et al. Lung ultrasound for the diagnosis of pneumonia in children: a meta-analysis. Pediatrics 2015; 135: 714-22.
25.
Urbankowska E, Krenke K, Drobczyński Ł, et al. Lung ultrasound in the diagnosis and monitoring of community acquired pneumonia in children. Respir Med 2015; 109: 1207-12.
26.
Musolino AM, Tomà P, Supino MC, et al. Lung ultrasound features of children with complicated and noncomplicated community acquired pneumonia: a prospective study. Pediatr Pulmonol 2019; 54: 1479-86.
27.
Copetti R, Cattarossi L. Diagnosi ecografica di polmonite nell’età pediatrica. Radiol Medica 2008; 113: 190-8.
28.
Volpicelli G. Lung sonography. J Ultrasound Med 2013; 32: 165-71.
29.
Miller A. Practical approach to lung ultrasound. BJA Educ 2016; 16: 39-45.
30.
Buonsenso D, Brancato F, Valentini P, et al. The use of lung ultrasound to monitor the antibiotic response of community-acquired pneumonia in children: a preliminary hypothesis. J Ultrasound Med 2019; 39: 817-26.
31.
Turker H, Hazar A, Ocakli B. Inflammatory markers in hospitalized patients with bacterial pneumonia: comparison of Gram-positive versus Gram-negative etiology and admission versus discharge findings. Arch Med Sci 2025; 21: 1372-80.
32.
Neuman MI, Hall M, Lipsett SC, et al. Utility of blood culture among children hospitalized with community-acquired pneumonia. Pediatrics 2017; 140: e20171013.
33.
Driscoll AJ, Karron RA, Morpeth SC, et al. Standardization of laboratory methods for the PERCH study. Clin Infect Dis 2017; 64 (Suppl 3): 245-52.
34.
Hammitt LL, Feikin DR, Scott JAG, et al. Addressing the analytic challenges of cross-sectional pediatric pneumonia etiology data. Clin Infect Dis 2017; 64 (Suppl 3): 197-204.